Erasca (ERAS)
(Delayed Data from NSDQ)
$2.75 USD
+0.19 (7.42%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $2.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Erasca, Inc. (ERAS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.83 | $7.00 | $3.00 | 88.67% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Erasca, Inc. comes to $4.83. The forecasts range from a low of $3.00 to a high of $7.00. The average price target represents an increase of 88.67% from the last closing price of $2.56.
Analyst Price Targets (6 )
Broker Rating
Erasca, Inc. currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy, representing 85.71% of all recommendations. A month ago, Strong Buy represented 85.71%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | Goldman Sachs | Chris Shibutani | Strong Buy | Strong Buy |
8/13/2024 | H.C. Wainwright & Co. | Andres Y Maldonado | Strong Buy | Strong Buy |
8/12/2024 | Capital One Securities | Naureen Quibria | Strong Buy | Strong Buy |
2/13/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.29 |
# of Recs in ABR | 7 |
Average Target Price | $4.83 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | -0.18 |
ERAS FAQs
Erasca, Inc. (ERAS) currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Erasca, Inc. (ERAS) is $4.83. The current on short-term price targets is based on 5 reports.
The forecasts for Erasca, Inc. (ERAS) range from a low of $3 to a high of $7. The average price target represents a increase of $75.64 from the last closing price of $2.75.
The current UPSIDE for Erasca, Inc. (ERAS) is 75.64%
Based on short-term price targets offered by six analysts, the average price target for Erasca, Inc. comes to $4.83. The forecasts range from a low of $3.00 to a high of $7.00. The average price target represents an increase of 88.67% from the last closing price of $2.56.